Joel Beatty has given his Buy rating due to a combination of factors related to PTC Therapeutics’ promising ... is the FDA’s decision to grant Fast Track Designation to PTC518 for Huntington ...

PTC Therapeutics announced that the FDA has granted Fast Track designation to the PTC518 programme for the treatment of Huntington's disease. Fast Track designation is awarded to promising therapies ...

PTC received Fast Track Designation for the PTC518 Huntington's disease program. PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024. PTC expects to ...

PTC Therapeutics Inc (PTCT) reports strong Q3 revenue and raises 2024 guidance, while navigating regulatory hurdles and ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

TOP STORIES FROM WESH: Special edition Stanley tumblers are selling out, but these are still in stock READ THE FULL STORY:PTC-9: Maps, track, spaghetti models ...

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients ...

The U.S. Food and Drug Administration (FDA) accepted the company's New Drug Application for sepiapterin, a potential treatment for phenylketonuria (PKU), and granted Fast Track Designation to PTC ...

PTC received Fast Track Designation for the PTC518 Huntington's disease program. PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024. PTC expects to ...